| A multidisciplinary group-based survivorship intervention for those living with multiple myeloma: a feasibility study N Eilert, NJ Murphy, H Cummins, E Houlihan, J Krawczyk Pilot and Feasibility Studies 10 (1), 100, 2024 | | 2024 |
| Extreme Symptom Burden for Patients With COVID-19 at the End of Life; Extrapolation of Knowledge Gained to Achieve Sustained Comfort and Dignity for all Patients in Their Last … D Waldron, CE Mc Carthy, D Murphy, J Krawczyk, L Kelly, F Walsh, ... American Journal of Hospice and Palliative Medicine® 41 (1), 113-118, 2024 | | 2024 |
| Safety and preliminary efficacy of mesenchymal stromal cell (ORBCEL-M) therapy in diabetic kidney disease: a randomized clinical trial (NEPHSTROM) N Perico, G Remuzzi, MD Griffin, P Cockwell, AP Maxwell, F Casiraghi, ... Journal of the American Society of Nephrology 34 (10), 1733-1751, 2023 | 14 | 2023 |
| Generation of three induced pluripotent stem cell lines from a patient with KCNQ2 developmental and epileptic encephalopathy as a result of the pathogenic variant c. 881C> T; p … R Stewart, C Gadoud, J Krawczyk, V McInerney, T O'Brien, S Shen, ... Stem Cell Research 71, 103191, 2023 | | 2023 |
| Generation of three induced pluripotent stem cell lines from a patient with KCNQ2 developmental and epileptic encephalopathy as a result of the pathogenic variant c. 638C> T; p … R Stewart, C Gadoud, J Krawczyk, V McInerney, T O'Brien, S Shen, ... Stem Cell Research 69, 103093, 2023 | 1 | 2023 |
| Immunotherapy: INITIAL CO-CULTURE WITH CLINICAL-GRADE UMBILICAL CORD-DERIVED MESENCHYMAL STROMAL CELL ENHANCES EX VIVO HUMAN REGULATORY T CELL EXPANSION Q Ou, S Hanley, N Negi, R Power, S Hontz, SJ Elliman, J Krawczyk, ... Cytotherapy 25 (6), S244, 2023 | | 2023 |
| Treatment and Disease-Related Complications in Multiple Myeloma L Al Kayyali, ZA Diak, OA Diak, J Krawczyk Recent Updates on Multiple Myeloma, 2023 | 1 | 2023 |
| Marrow changes and reduced proliferative capacity of mesenchymal stromal cells from patients with “no-option” critical limb ischemia; observations on feasibility of the … SA Mohamed, A Duffy, V McInerney, J Krawczyk, A Hayat, S Naughton, ... Cytotherapy 24 (12), 1259-1267, 2022 | 1 | 2022 |
| TRAIL Engineering Enhances Expanded Cord Blood NK Cell Anti-Leukemic Activity M Gurney, M Twohig, DG Helvaci, E O'Reilly, S Brophy, J Krawczyk, ... Blood 140 (Supplement 1), 10249-10250, 2022 | | 2022 |
| Reference intervals for clinical biochemistry and haematology tests during normal pregnancy W Groenendijk, D Bogdanet, L Dervan, O Finn, MN Islam, H Doheny, ... Annals of Clinical Biochemistry 59 (6), 433-446, 2022 | 4 | 2022 |
| Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor–natural killer cells M Gurney, E O'Reilly, S Corcoran, S Brophy, J Krawczyk, NM Otto, ... Cytotherapy 24 (11), 1087-1094, 2022 | 11 | 2022 |
| CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment D Swan, R Henderson, C McEllistrim, SD Naicker, J Quinn, MR Cahill, ... Clinical Lymphoma Myeloma and Leukemia 22 (11), 847-852, 2022 | 1 | 2022 |
| MiRNA as a Potential Target for Multiple Myeloma Therapy–Current Knowledge and Perspectives A Szudy-Szczyrek, S Ahern, J Krawczyk, M Szczyrek, M Hus Journal of Personalized Medicine 12 (9), 1428, 2022 | 7 | 2022 |
| Inhibition of IRE1α RNase activity sensitizes patient‐derived acute myeloid leukaemia cells to proteasome inhibitors S Creedican, CM Robinson, K Mnich, MN Islam, E Szegezdi, R Clifford, ... Journal of Cellular and Molecular Medicine 26 (16), 4629, 2022 | 2 | 2022 |
| Corrigendum to" Derivation of familial iPSC lines from three patients with retinitis pigmentosa carrying an autosomal dominant RPE65 mutation (NUIGi027-A, NUIGi028-A, NUIGi029 … Y Ding, E Carvalho, C Murphy, V McInerney, J Krawczyk, T O'Brien, ... Stem cell research 63, 102850, 2022 | | 2022 |
| A NOVEL, MULTI-SITE GMP PROTOCOL TO MANUFACTURE PROSPECTIVELY-ISOLATED, ALLOGENEIC BONE MARROW MSCS FOR A PHASE 1B CLINICAL TRIAL IN PROGRESSIVE DIABETIC KIDNEY DISEASE H Roelofs, E Steeneveld, O Pedrini, J Golay, A Duffy, V McInerney, ... CYTOTHERAPY 24 (5), S51-S51, 2022 | | 2022 |
| Mesenchymal Stem/Stromal Cells: A NOVEL, MULTI-SITE GMP PROTOCOL TO MANUFACTURE PROSPECTIVELY-ISOLATED, ALLOGENEIC BONE MARROW MSCS FOR A PHASE 1B CLINICAL TRIAL IN PROGRESSIVE … H Roelofs, E Steeneveld, O Pedrini, J Golay, A Duffy, V McInerney, ... Cytotherapy 24 (5), S51, 2022 | | 2022 |
| Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma P O'Gorman, JP Laubach, ME O'Dwyer, J Krawczyk, AJ Yee, O Gilligan, ... American Journal of Hematology 97 (5), 562-573, 2022 | 3 | 2022 |
| GMP-Compliant Production of Autologous Adipose-Derived Stromal Cells in the NANT 001 Closed Automated Bioreactor. G Cattaruzzi, F Vitrani, F Mazzarol, P Mauro, A Sfiligoj, F Curcio, ... | | 2022 |
| GMP-compliant production of autologous adipose-derived stromal cells in the NANT 001 closed automated bioreactor JC Fitzgerald, N Duffy, G Cattaruzzi, F Vitrani, A Paulitti, F Mazzarol, ... Frontiers in Bioengineering and Biotechnology 10, 834267, 2022 | 2 | 2022 |
Michael O'DwyerHaematology在 nuigalway.ie 的电子邮件经过验证
